THE DONOWAY CENTER New Clinical Trial Available Now for Patients with Advanced & Metastatic Pancreatic Cancer
Are you, or someone you know, being treated for Advanced or Metastatic Pancreatic Cancer with chemotherapy alone? Contact Dr. Robert Donoway at Atlas Oncology in Hollywood, Florida. Dr. Donoway is leading a new clinical trial using multi-modality therapy: combining Pancreatic Nanoknife Ablation with chemoimmuno-radiotherapy to treat advanced stage cancer patients from around the world. With over 35 years of experience performing pancreatic surgery in South Florida, Dr. Donoway recognized that, because of its late diagnosis, up to 85% of the patients treated with surgery for pancreatic cancer already had metastatic disease. This fact limits the benefit a patient might get from the Whipple surgery. Recent evidence shows that when even advanced disease is treated aggressively in an integrated approach, incorporating Nanoknife surgery with chemotherapy, long-term survivorship can be achieved, especially compared to chemotherapy alone. Dr. Donoway has been a pioneer in the use of Pancreatic NanoKnife, especially for complex advanced cases. During the past decade, he remains the only surgical oncologist performing the procedure in South Florida. Patients from around the globe have traveled to benefit from this ground-breaking treatment, which is
FDA approved. Dr. Donoway also treats other advanced cancers, such as liver, breast, and sarcomas, using Nanoknife surgery. A brief recovery means the patient can start chemotherapy and radiation that much sooner. Dr. Donoway feels that “we are long overdue to revise our approach to treating pancreatic cancer. The treatment has remained largely unchanged for over 80 years and has just broken the 9-10% five-year survivorship barrier. Only thru thinking outside the box will we accomplish the positive. Otherwise, all we’re doing is confirming Einstein’s definition of Insanity.” Dr. Donoway is participating in several clinical studies identifying the best chemotherapy and immunotherapies to be used along with IRE. Dr. Donoway states, “The results so far have been very encouraging and we have begun using it for other select cancers. Among his longest survivors are now patients over eight years without evidence of cancer recurrence. In the past, without IRE they would have been likely to have only lived a year and so this technique opens the whole new avenue for treating those eligible patients in a more targeted fashion.” Dr. Donoway will be presenting the long-term results of his pancreatic treatment paradigm for advanced and metastatic disease later this fall at an International cancer society in Europe For more information about Dr. Donoway and the PancreaticIRE/NanoKnife Program and clinical trials call 305-682-1995 and visit www.AtlasOncology.com.
4000 Hollywood Boulevard • Suite 160 North • Hollywood, Florida 33021 Phone 954-986-6366, 305-682-1995 • Fax 954-986-4355 www.AtlasOncology.com
